Fang Chen

发表

Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial.

D. Torigian, M. Soulen, B. Levine, 2018, Gastroenterology.

Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma

D. Torigian, E. Wherry, J. Melenhorst, 2018, Oncoimmunology.

Ruxolitinib Prevents Cytokine Release Syndrome after CART Cell Therapy without Impairing the Anti-Tumor Effect in a Xenograft Model

Carl H. June, C. June, J. Melenhorst, 2016 .

Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy.

D. Teachey, S. Grupp, D. Porter, 2016, Journal of immunological methods.

CRISPR-engineered T cells in patients with refractory cancer

Howard Y. Chang, Wei-Ting Hwang, Frederic D Bushman, 2020, Science.

B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.

Weiss, Iulian Pruteanu-Malinici, B. Levine, 2019, The Journal of clinical investigation.

Ruxolitinib Prevents Cytokine Release Syndrome after Car T-Cell Therapy Without Impairing the Anti-Tumor Effect in a Xenograft Model

C. June, J. Melenhorst, M. Klichinsky, 2017 .

Dominant-Negative TGF- b Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication a phase I clinical trial to assess these CAR T cells as a novel approach for patients with relapsed and refractory metastatic prostate cancer

C. June, J. Melenhorst, Jihyun Lee, 2018 .

Author Correction: Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

Sadik H. Kassim, E. Wherry, F. Johnson, 2021, Nature Medicine.

Novel Correlation between B Cell Survival Cytokines and Inhibitors in Hemophilia A

V. Arruda, L. Raffini, S. Lacey, 2017 .

Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication.

C. June, J. Melenhorst, Jihyun Lee, 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

CAR T-cell therapy for triple-negative breast cancer: Where we are.

Y. Hu, Fang Chen, Lixin Wu, 2020, Cancer letters.

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

Hans Bitter, Wei-Ting Hwang, Iulian Pruteanu-Malinici, 2018, Nature Medicine.

PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial

F. Bushman, R. Sebro, B. Levine, 2022, Nature Medicine.

Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells

Tyler J. Reich, F. Bushman, S. Carty, 2018, Nature.

Engineered T Cell Therapies from a Drug Development Viewpoint

C. June, J. Melenhorst, S. Lacey, 2019, Engineering.

Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia.

G. Wertheim, D. Teachey, S. Grupp, 2016, Cancer discovery.

Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications

Sasikanth Manne, John P. Reilly, Allison R. Greenplate, 2020, Science.

Posterior Reversible Encephalopathy Syndrome (PRES) after Infusion of Anti-Bcma CAR T Cells (CART-BCMA) for Multiple Myeloma: Successful Treatment with Cyclophosphamide

B. Levine, C. June, J. Melenhorst, 2016 .

Endothelial Biomarkers Are Associated With Indirect Lung Injury in Sepsis-Associated Pediatric Acute Respiratory Distress Syndrome

J. Melenhorst, N. Yehya, S. Parikh, 2020, Critical care explorations.

Deep immune profiling of COVID-19 patients reveals patient heterogeneity and distinct immunotypes with implications for therapeutic interventions

Sasikanth Manne, John P. Reilly, Allison R. Greenplate, 2020, bioRxiv.

Title : Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T cell Therapy for Acute Lymphoblastic Leukemia

G. Wertheim, D. Teachey, S. Grupp, 2016 .

Temperature Trajectory Sub-phenotypes and the Immuno-Inflammatory Response in Pediatric Sepsis

D. Teachey, J. Melenhorst, N. Yehya, 2021, Shock.

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

Sadik H. Kassim, E. Wherry, H. Bitter, 2018, Nature Medicine.

Neurotoxicity after CTL019 in a pediatric and young adult cohort

D. Teachey, S. Grupp, B. Banwell, 2018, Annals of neurology.

Safety and Efficacy of B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) with Cyclophosphamide Conditioning for Refractory Multiple Myeloma (MM)

B. Levine, C. June, J. Melenhorst, 2017 .

B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) for Multiple Myeloma (MM): Initial Safety and Efficacy from a Phase I Study

B. Levine, C. June, J. Melenhorst, 2016 .

Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children.

Jason W. Moore, D. Teachey, S. Grupp, 2020, Blood advances.

Systemic Endothelial Activation Is Associated With Early Acute Respiratory Distress Syndrome in Children With Extrapulmonary Sepsis*

D. Teachey, J. Melenhorst, N. Yehya, 2020, Critical care medicine.

Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CTL019) in Conjunction with Salvage Autologous Stem Cell Transplantation for Advanced Multiple Myeloma

D. Porter, B. Levine, C. June, 2016 .

Identification of Functional Determinants of Response and Resistance to CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy of Chronic Lymphocytic Leukemia

E. Wherry, F. Johnson, H. Bitter, 2017 .

Autologous CD4 T Lymphocytes Modified with a Tat-Dependent, Virus-Specific Endoribonuclease Gene in HIV-Infected Individuals.

B. Levine, C. June, W. Hwang, 2020, Molecular therapy : the journal of the American Society of Gene Therapy.

Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy

G. Linette, C. June, W. Hwang, 2022, Blood cancer discovery.

Biomarkers Accurately Predict Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Acute Lymphoblastic Leukemia (ALL)

D. Teachey, S. Grupp, D. Porter, 2015 .

Two Cases of Severe Pulmonary Toxicity from Highly Active Mesothelin-Directed CAR T Cells.

Ryan J. Golden, C. June, Xiaojun Liu, 2023, Molecular therapy : the journal of the American Society of Gene Therapy.

Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Relapsed/Refractory (R/R) CLL

D. Teachey, S. Grupp, D. Porter, 2014 .

Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells

Tyler J. Reich, F. Bushman, S. Carty, 2018, Nature.

Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell Associated Neurotoxicity Syndrome in B-Cell ALL Patients Receiving CART19.

D. Teachey, A. Seif, S. Grupp, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.

Iulian Pruteanu-Malinici, W. Hwang, J. Brogdon, 2019, The Journal of clinical investigation.